1-methyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | 19697-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-methyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• 英文别名: 6-hydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid；1-Methyl-6-hydroxy-1,2,3,4-tetrahydro-isochinolin-3-carbonsaeure；6-hydroxy-1-methyl-tetrahydroisoquinoline-3-carboxylic acid；1-Methyl-6-hydroxyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• CAS: 19697-94-0
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: ZROUARAECJDWIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020065248A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of Formula (I): 1 wherein A 1 is methylene, ethylene or propylene group and A 2 is N or CR 5 , or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及化合物的结构公式（I）：其中A1为亚甲基、乙烯基或丙烯基，A2为N或CR5，或其立体异构体形式、立体异构体混合物或药用盐形式，用作HCV NS3蛋白酶的抑制剂，以及包含相同化合物的药物组合物和诊断试剂盒，以及用于治疗病毒感染或作为测定标准或试剂的方法。
• Antibiotics napsamycins A-D, process for their production and their use as pharmaceuticals
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0487756A1

  公开（公告）日：1992-06-03

  This invention relates to new antibacterial antibiotics Napsamycins A - D of the formula Napsamycin A :R¹ = H, R² = uracil Napsamycin B :R¹ = CH₃, R² = uracil Napsamycin C :R¹ = H, R² = dihydrouracil Napsamycin D :R¹ = CH₃, R² = dihydrouracil from a strain of Streptomyces candidus, Y-82,11372 (DSM 5940).

  这项发明涉及新的抗菌抗生素Napsamycins A - D，其化学式如下： Napsamycin A：R¹ = H，R² = 尿嘧啶 Napsamycin B：R¹ = CH₃，R² = 尿嘧啶 Napsamycin C：R¹ = H，R² = 脱氢尿嘧啶 Napsamycin D：R¹ = CH₃，R² = 脱氢尿嘧啶，来源于链霉菌Streptomyces candidus的一株Y-82,11372（DSM 5940）。
• Peptide inhibitors of hepatitis C virus NS3 protein
  申请人：——

  公开号：US20020177725A1

  公开（公告）日：2002-11-28

  This invention relates to a novel class of peptides having the Formula (I): 1 Which are useful as serine protease inhibitors, and more particularly as Hepatitis C virus(HCV) NS3 protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same in the treatment of HCV infection.

  本发明涉及一类新型肽的公式(I)：1，其作为丝氨酸蛋白酶抑制剂具有用途，更具体地作为丙型肝炎病毒（HCV）NS3蛋白酶抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗HCV感染的方法。
• [EN] ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE<br/>[FR] INHIBITEURS D'ALPHA-CETOAMIDES DE LA PROTEASE NS3 DU VIRUS DE L'HEPATITE C
  申请人：DU PONT PHARM CO

  公开号：WO2001040262A1

  公开（公告）日：2001-06-07

  The present invention relates to ketoamide and ketoester compounds of Formula (I): where W is -NH- or -O-, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及式(I)的酮酰胺和酮酯化合物：其中W为-NH-或-O-，或其立体异构体、立体异构体混合物或药学上可接受的盐形式，它们可用作HCV NS3蛋白酶的抑制剂，以及包含它们的制药组合物和诊断试剂盒，以及将它们用于治疗病毒感染或作为测定标准或试剂的方法。
• Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
  申请人：——

  公开号：US20020123468A1

  公开（公告）日：2002-09-05

  The present invention relates to ketoamide and ketoester compounds of Formula (I): 1 wherein W is —NH— or —O—, or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HCV NS3 protease, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

  本发明涉及公式（I）的酮酰胺和酮酯化合物：1其中W为-NH-或-O-，或其立体异构体形式，立体异构体混合物或其药学上可接受的盐形式，它们可用作HCV NS3蛋白酶的抑制剂，以及包含它们的制药组合物和诊断试剂盒，以及将它们用于治疗病毒感染或作为测定标准或试剂的方法。